It looks like there is a follow-on study being done at the University of Wisconsin, by Adam Konopka and the team there. If you live in the area, I recommend you join the study. We need much more data on rapamycin in healthy people, so I’m glad to see this research being done (and still funded).
Can Rapamycin slow aging?
Overview
As people age, the risk for developing chronic diseases and conditions increases. The FDA approved drugs rapamycin (sirolimus) and rapamycin analogs (everolimus) increase the quality and quantity of lifespan in animals. It remains unknown if the same could be true for humans. The purpose of this research study is to learn if the rapamycin analog everolimus can help improve or maintain the health and function of adults 55-80 years old who may have insulin resistance or pre-diabetes. As a part of this study, you will be asked to take low doses of everolimus or placebo once daily and once weekly for 24-weeks. There will be several assessments before, during and after the 24 weeks. These include blood and muscle sampling, and measurements of body composition, metabolism, exercise capacity (VO2max), and brain and heart health. All visits are located at the University of Wisconsin- Madison campus and you will be compensated up to $2000 for your time.
You May Qualify to Participate if you meet the following:
- Are between the ages of 55-80 years old
- Are not taking medications to lower glucose or that prolong bleeding
- Have pre-diabetes or insulin resistance, but are otherwise healthy
- This would include an elevated fasting glucose (100-125 mg/dL) or HbA1c (5.7-6.4%). If you do not know if you have values consistent with pre-diabetes or insulin resistance, we can help determine this for you at no cost.
Participants Will:
- Take a pill once daily and once weekly for 24 weeks
- Be monitored by physicians and study team before, during, and after the course of the study
- Complete a variety of health tests as shown in the Study Schematic below.
- These include exercise testing, blood and muscle sampling, heart and brain imaging, glucose testing and continuous glucose monitoring (CGM), and a body composition scan (DEXA Scan)
- You will be compensated up to $2000 for your time!
https://konopkalab.medicine.wisc.edu/clinical-trials/everlast/
And a local (Wisconsin) news story on the study:
Could a drug slow aging? UW-Madison researchers seek answers in trial
University of Wisconsin-Madison researchers are studying whether a drug used for organ transplant patients could slow aging in humans.
Some compelling evidence in recent decades shows rapamycin — also known as sirolimus — can increase the quality and quantity of life in animals, said Adam Konopka, a UW-Madison assistant professor of geriatrics and gerontology.
“This got people really excited that maybe this drug could be used to improve human healthy longevity,” he said.
The New York Times and Washington Post have reported on the growing popularity of people taking rapamycin off-label in an attempt to live healthier longer. While it remains unclear whether the benefits reported in animals could extend to humans, Konopka said he hopes a clinical trial he’s working on will provide more insights.
“I think by the end of it we’ll be able to have a really good idea of whether this drug can have any sort of positive or even detrimental effects for humans,” Konopka said.
Funded by the National Institute on Aging, Konopka’s lab has worked on the clinical trial for the last few years and recruitment wrapped up in late 2025.
“The next six months will be largely focused on completing data collection, and then we’ll move on to a bunch of analysis in the summer of 2026,” Konopka said.
People can still sign up for a related study through Konopka’s lab. Participants may receive up to $600 for completing the study.
What’s unique about your research?
Our trial is a double-blinded, placebo-controlled trial that has enrolled over 84 participants and is testing whether 24 weeks of rapamycin can help prevent the decline or improve outcomes linked to healthy aging.
One unique aspect is that it is comprehensive. We are largely focused on metabolic health, but we’re also studying heart, brain and physical function.
As we get older, I think people can appreciate that those are some of the first things that they start to see change.
Read the Full story here: